Guidelines for Thyroid Function During Pregnancy: Evidence-Based Clinical Review

Abstract

Thyroid dysfunction during pregnancy is a well-recognized contributor to adverse maternal and fetal outcomes. This review synthesizes current evidence on the epidemiology, pathophysiology, clinical features, diagnostic approaches, and management of thyroid disorders in pregnancy, with a focus on recent guideline recommendations. Emphasis is placed on the importance of early detection, appropriate therapeutic interventions, and a multidisciplinary approach tailored to gestational physiology. The paper discusses both overt and subclinical thyroid dysfunctions and offers practical insights for clinicians navigating the complexities of thyroid hormone assessment and replacement during gestation. Recent advances in diagnostic thresholds, therapeutic targets, and individualized patient care underscore the evolving landscape of thyroidology in obstetric practice.

Introduction

Thyroid hormones are essential for normal fetal neurodevelopment and maternal health throughout gestation. The physiological adaptations of pregnancy, including increased thyroid hormone demand and altered immune tolerance, render the maternal thyroid gland susceptible to dysfunction. Both hypothyroidism and hyperthyroidism, whether overt or subclinical, have been associated with miscarriage, preterm delivery, preeclampsia, and neurodevelopmental deficits in offspring. Timely recognition and management of thyroid disorders during pregnancy are therefore fundamental components of obstetric care. This review provides a comprehensive, evidence-based summary of thyroid function guidelines in pregnancy, integrating recent research and global consensus statements to guide clinical practice.

Epidemiology / Disease Burden

Thyroid disorders are among the most common endocrine diseases affecting pregnant women. The prevalence of overt hypothyroidism in pregnancy is estimated at 0.3–0.5%, while subclinical hypothyroidism may affect up to 2–3% of pregnancies. Hyperthyroidism, predominantly due to Graves' disease, occurs less frequently, with an incidence of approximately 0.1–0.4%. Subclinical hyperthyroidism is rarer but may be underdiagnosed. Autoimmune thyroiditis, particularly Hashimoto's thyroiditis, is the leading cause of hypothyroidism in iodine-sufficient populations. The burden of undiagnosed or inadequately managed thyroid dysfunction is significant, given its association with increased maternal morbidity, impaired fetal neurodevelopment, and long-term sequelae for both mother and child.

Pathophysiology

During pregnancy, several physiological changes impact thyroid function. Elevated estrogen levels increase thyroxine-binding globulin (TBG), raising total thyroid hormone concentrations. Human chorionic gonadotropin (hCG) exerts a weak thyrotropic effect, especially in the first trimester, transiently lowering serum thyroid-stimulating hormone (TSH) and stimulating thyroid hormone synthesis. The placenta also expresses deiodinase enzymes, modulating fetal thyroid hormone exposure. Iodine requirements increase by approximately 50% due to increased renal clearance and fetal needs. Failure to adapt to these changes can precipitate hypothyroidism or hyperthyroidism, with distinct clinical and biochemical profiles.

Risk Factors

Risk factors for thyroid dysfunction in pregnancy include a personal or family history of thyroid disease, the presence of thyroid autoantibodies (anti-thyroid peroxidase or anti-thyroglobulin), previous head or neck irradiation, autoimmune diseases (especially type 1 diabetes mellitus), advanced maternal age, and residence in iodine-deficient regions. Assisted reproductive technologies, prior pregnancy loss, and obesity are also associated with increased risk. Routine risk assessment and targeted screening are advocated by leading guidelines in women with these predisposing factors.

Clinical Features

Clinical manifestations of thyroid dysfunction in pregnancy may be subtle or confounded by normal gestational symptoms. Hypothyroidism typically presents with fatigue, weight gain, cold intolerance, constipation, and bradycardia, though these may overlap with pregnancy-related changes. More severe forms can cause myxedema or, rarely, myxedema coma. Hyperthyroidism may manifest as anxiety, palpitations, weight loss, heat intolerance, and tremors. Untreated, it can progress to thyroid storm a life-threatening complication. Both disorders can present with goiter or ophthalmopathy in autoimmune cases. Importantly, subclinical forms are often asymptomatic and detected only by biochemical screening.

Diagnosis

Diagnosis of thyroid dysfunction in pregnancy relies on trimester-specific reference ranges for TSH and free thyroxine (FT4). The American Thyroid Association (ATA) recommends a TSH upper limit of 4.0 mIU/L in the first trimester, with local laboratory ranges preferred if available. Isolated TSH elevation with normal FT4 defines subclinical hypothyroidism; overt hypothyroidism is characterized by elevated TSH with low FT4. Hyperthyroidism is diagnosed by suppressed TSH and elevated FT4 or free triiodothyronine (FT3). Thyroid autoantibody testing is useful for etiological clarification. Total T4 and FT4 index may be used if FT4 assays are unreliable. Universal screening remains controversial; however, targeted case-finding based on risk factors is widely endorsed.

Treatment & Management

Levothyroxine is the treatment of choice for hypothyroidism in pregnancy. The goal is to normalize TSH within trimester-specific ranges, with dose adjustments as early as possible after conception often requiring a 30–50% increase. Subclinical hypothyroidism with positive thyroid peroxidase antibodies or TSH above 4.0 mIU/L generally warrants treatment. Hyperthyroidism is managed primarily with antithyroid drugs: propylthiouracil (PTU) is preferred in the first trimester due to lower teratogenic risk, switching to methimazole in the second trimester if needed. Beta-blockers may be used short-term for symptomatic relief. Radioactive iodine is contraindicated. Surgery is reserved for refractory or malignant cases. Close monitoring of maternal thyroid function every 4–6 weeks is crucial to avoid under- or overtreatment, both of which have deleterious fetal consequences.

Recent Advances / Emerging Therapies

Recent years have seen refinement of diagnostic thresholds and greater recognition of the role of thyroid autoimmunity in adverse pregnancy outcomes. Advances in immunoassay technology have improved the accuracy of FT4 measurements. There is growing interest in the potential benefits and risks of treating isolated maternal hypothyroxinemia and subclinical hypothyroidism without autoantibodies. Ongoing studies are evaluating the impact of selenium supplementation and novel immunotherapies for autoimmune thyroid disease. Personalized medicine approaches, including pharmacogenomics, are beginning to influence dose adjustment and monitoring strategies in thyroid hormone replacement. Updated guidelines increasingly emphasize individualized care and shared decision-making, particularly in borderline cases.

Guideline Recommendations

Current ATA and Endocrine Society guidelines recommend targeted screening based on risk factors rather than universal testing. Trimester-specific TSH reference ranges should be used, and levothyroxine should be initiated for overt hypothyroidism and for subclinical hypothyroidism with TSH >4.0 mIU/L, particularly in antibody-positive women. Antithyroid medications should be minimized to the lowest effective dose, and fetal monitoring is recommended in cases of poorly controlled maternal hyperthyroidism. Preconception counseling and optimization of thyroid status are advocated for all women of reproductive age with known thyroid disease. Iodine supplementation is recommended in areas of deficiency, and close interprofessional collaboration between endocrinologists, obstetricians, and primary care providers is emphasized throughout pregnancy and postpartum.

Conclusion

Optimal management of thyroid function during pregnancy requires a nuanced understanding of gestational physiology, evidence-based screening, and individualized therapeutic strategies. Early identification and appropriate treatment of thyroid dysfunction can significantly reduce maternal and fetal morbidity. Ongoing research continues to refine diagnostic and management paradigms, highlighting the importance of staying abreast of evolving guidelines. Multidisciplinary collaboration and patient-centered care remain the cornerstones of mitigating the risks associated with thyroid disorders in pregnancy and ensuring the best possible outcomes for both mother and child.